BTG given approval for varicose vein treatment by FDA

26th Nov 2013 11:45

Healthcare company BTG has received approval from the US Food and Drug Administration (FDA) for its Varithena treatment. Varithena, which previously went under the name of Varisolve, is used to treat varicose veins, which can cause a range of symptoms. Current treatments for varicose veins include thermal ablation and surgery, but Varithena is administered as a minimally invasive, non-surgical procedure which doesn't require anesthesia or sedation. Louise Makin, Chief Executive at BTG, said: "We are delighted to receive US approval for Varithena, which we believe sets a new standard for the treatment of both the symptoms and appearance of varicose veins. "We look forward to the commercial US launch in the second quarter of 2014, and to continuing to advance our plans to expand use into other geographies and into non-symptomatic veins."NR